Evidence map›Paper›PMID 40412807›Full record

Observational studyOphthalmology. Glaucoma

The Rate of Failure of Trabeculectomy and Tube Shunt Surgery in Eyes with Uveitic Glaucoma and Ocular Hypertension.

Sylvia L Groth, Craig W Newcomb, Wei Yang, Abhishek Payal, Hosne Begum, Naira Khachatryan, R Oktay Kaçmaz, Kurt A Dreger, James T Rosenbaum, H Nida Sen and 11 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Ophthalmology. Glaucoma. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sylvia L GrothVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: sylviagroth@gmail.com.
Craig W NewcombCenter for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Wei YangDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania.
Abhishek PayalMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; The Tampa Bay Uveitis Center, St. Petersburg, Florida.
Hosne BegumWilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Naira KhachatryanDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania.
R Oktay KaçmazSanten Inc., Emeryville, California.
Kurt A DregerWilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Population, Family, and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
James T RosenbaumDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon; Department of Medicine, Oregon Health and Science University, Portland, Oregon; Legacy Devers Eye Institute, Portland, Oregon.
H Nida SenLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Eric B SuhlerDepartment of Medicine, Oregon Health and Science University, Portland, Oregon; Legacy Devers Eye Institute, Portland, Oregon.
Jennifer E ThorneWilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Nirali P BhattScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
C Stephen FosterMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Douglas A JabsWilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Grace A Levy-ClarkeThe Tampa Bay Uveitis Center, St. Petersburg, Florida; Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
Jeanine M BuchanichCenter for Occupational Biostatistics and Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.
Gui-Shuang YingScheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
John H KempenDepartment of Ophthalmology, Harvard Medical School, Boston, Massachusetts; Department of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; Department of Ophthalmology, Addis Ababa University School of Medicine, Addis Ababa, Ethiopia; MCM Eye Unit; MyungSung Christian Medical Center (MCM) Comprehensive Specialized Hospital and MyungSung Medical College, Addis Ababa, Ethiopia.
Sapna GangaputraVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee.
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Research Group

Funding

Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1M
Outcomes of uveitic cataract and uveitic glaucoma surgeryR21EY032592 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GANGAPUTRA, SAPNA S · 2021 to 2022
$488k
NEI NIH HHS R01 EY014943NEI NIH HHS R21 EY032592
6 · The paper itself

Abstract

purposeTo evaluate the incidence of failure of trabeculectomy versus tube shunt (TS) glaucoma surgery in eyes of patients with uveitis.

designMulticenter retrospective cohort study.

participantsAmong 356 eyes of 288 patients with noninfectious inflammatory eye disease undergoing first incisional glaucoma surgery using one of the techniques, 244 eyes had TSs, and 112 eyes had trabeculectomy augmented with mitomycin-C (Trab-MMC).

methodsA standardized chart review was used to collect clinical data over time retrospectively. Cox regression analyses with adjustment for propensity score and intereye correlations were performed to compare the incidence of failure of glaucoma surgery between TS and Trab-MMC.

main outcome measuresFailure of glaucoma surgery of the first 5 years postoperatively, defined as the following: (1) intraocular pressure (IOP) ≤ 5 or > 21 mmHg at 2 consecutive visits at least 90 days apart beginning 3 months after surgery; or (2) reoperation; or (3) complete blindness (no light perception).

resultsThe median age was 40.3 years (interquartile range [IQR], 13.4-57.3 years) in the TS group and 44.2 years (IQR, 29.0-58.9 years) in the Trab-MMC group. The median preglaucoma surgery IOP was 30.0 mmHg (IQR, 21-35.5 mmHg) in the TS group and 30.5 mmHg (IQR, 20-38 mmHg) in the Trab-MMC group. Anterior uveitis was the most common location of primary inflammation in both the TS (52.5%) and Trab-MMC 55.4%) groups. Failure was observed in the TS group in 23.5%, 27.1%, and 30.8% cumulatively through 12, 24, and 36 months, respectively, versus 16.1%, 25.6%, and 30.0%, respectively, in the Trab-MMC group. In the propensity score-adjusted Cox regression analysis, there was no significant difference in failure incidence rate between the TS and Trab-MMC groups (adjusted hazard ratio, 1.08; 95% confidence interval, 0.65-1.78; P = 0.77). Success without the requirement for IOP-lowering medicines was observed more frequently in the Trab-MMC group.

conclusionsTube shunt and Trab-MMC fail frequently with similar incidences when done as the first glaucoma surgery among eyes with uveitis over 5 years of follow-up, but there were more complete successes in the Trab-MMC group than in the TS group at 12, 24, and 36 months. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

GlaucomaGlaucoma Drainage ImplantsIntraocular PressureOcular HypertensionTrabeculectomyUveitisAdolescentAdultFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesTreatment FailureVisual AcuityGlaucoma filtering surgerySecondary glaucomaUveitic glaucomaUVEITIS

Identifiers

PMID40412807
PMCPMC13617674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.